menu
    • menu
    [{"orgOrder":0,"company":"Aethlon Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aethlon Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aethlon Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aethlon Medical \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Starpharma

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Genentech

                            Deal Size : $569.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Starpharma Announces a Collaboration and License Agreement with Genentech

                            Details : Starpharma will employ its proprietary DEP® platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $5.5 million

                            September 22, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Genentech

                            Deal Size : $569.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immutep

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immutep

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eftilagimod Alpha,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD...

                            Details : The claims of the new patent protect combined therapeutic preparations comprising MP321 (eftilagimod alpha), which is a soluble LAG-3 fusion protein (LAG-3Ig), and an antiPD-1 or anti-PD-L1 antibody to manufacture of medicament for treatment of cancer an...

                            Product Name : Efti

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 15, 2021

                            Lead Product(s) : Eftilagimod Alpha,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aethlon Medical

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aethlon Medical

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

                            Details : Keytruda (Pembrolizumab) is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Keytruda

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 01, 2020

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth